This year’s theme was focused on “Caring for Every Patient, Learning From Every Patient”. The conference brought together more than 42 000 oncology professionals from around the globe to promote communication among oncology-related sub-specialties and the exchange of the latest findings from clinical research studies of novel treatments, cancer risk, survivorship and the value of cancer care.

Previous studies have demonstrated that extended therapy with an aromatase inhibitor (either letrozole, exemestane, or anastrozole) after 5 years of tamoxifen improves disease free survival (DFS) in breast cancer patients.

Please sign in to read more